We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Emerald Health Pharmaceuticals (EHP) has initiated activities for a Phase 2 international clinical study for the treatment of patients with multiple sclerosis (MS).
Emerald Health Pharmaceuticals (EHP) has begun enrollment and has dosed its first patients with diffuse cutaneous systemic sclerosis (dcSSc) in its Phase 2a clinical study of its lead product candidate, EHP-101.